Skip to main content
Erschienen in: Skeletal Radiology 3/2018

01.03.2018 | Scientific Article

Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma

verfasst von: M. Horger, J. Fritz, W. M. Thaiss, H. Ditt, K. Weisel, M. Haap, Christopher Kloth

Erschienen in: Skeletal Radiology | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare qualitative and quantitative computed tomography (CT) and magnetic resonance imaging (MRI) parameters for longitudinal disease monitoring of multiple myeloma (MM) of the axial skeleton.

Materials and methods

We included 31 consecutive patients (17 m; mean age 59.20 ± 8.08 years) with MM, who underwent all baseline (n = 31) and at least one or more (n = 47) follow-up examinations consisting of multi-parametric non-enhanced whole-body MRI (WBMRI) and non-enhanced whole-body reduced-dose thin-section MDCT (NEWBMDCT) between 06/2013 and 09/2016. We classified response according to qualitative CT criteria into progression (PD), stable(SD), partial/very good partial (PR/VGPR) and complete response(CR), grouping the latter three together for statistical analysis because CT cannot reliably assess PR and CR. Qualitative MR-response criteria were defined and grouped similarly to CT using longitudinal quantification of signal-intensity changes on T1w/STIR/ T2*w and calculating ADC-values. Standard of reference was the hematological laboratory (M-gradient).

Results

Hematological response categories were CR (14/47, 29.7%), PR (2/47, 4.2%), SD (16/47, 34.0%) and PD (15/47, 29.9%). Qualitative-CT-evaluation showed PD in 12/47 (25.5%) and SD/PR/VGPR/CR in 35/47 (74.5%) cases. These results were confirmed by quantitative-CT in all focal lytic lesions (p < 0.001). Quantitative-CT at sites with diffuse bone involvement showed significant increase of maximum bone attenuation (p < 0.001*) and significant decrease of minimal bone (p < 0.002*) in the SD/PR/VGPR/CR group. Qualitative MRI showed PD in 14/47 (29.7%) and SD/PR/VGPR/CR in 33/47 (70.3%). Quantitative MRI diagnosis showed a statistically significant decrease in signal intensity on short tau inversion recovery sequences (STIR) in bone marrow in patients with diffuse bone marrow involvement achieving SD/PR/VGPR/CR (p < 0.001*).

Conclusion

Imaging response monitoring using MRI is superior to CT only if qualitative parameters are used, whereas there was no definite benefit from using quantitative parameters with either CT or MRI.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Lin C, Luciani A, Belhadj K, Deux JF, Kuhnowski F, Maatouk M, et al. Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology. 2010;254(2):521–31.CrossRefPubMed Lin C, Luciani A, Belhadj K, Deux JF, Kuhnowski F, Maatouk M, et al. Multiple myeloma treatment response assessment with whole-body dynamic contrast-enhanced MR imaging. Radiology. 2010;254(2):521–31.CrossRefPubMed
3.
Zurück zum Zitat Ferraro R, Agarwal A, Martin-Macintosh EL, Peller PJ, Subramaniam RM. MR imaging and PET/CT in diagnosis and management of multiple myeloma. Radiographics. 2015;35(2):438–54.CrossRefPubMed Ferraro R, Agarwal A, Martin-Macintosh EL, Peller PJ, Subramaniam RM. MR imaging and PET/CT in diagnosis and management of multiple myeloma. Radiographics. 2015;35(2):438–54.CrossRefPubMed
4.
Zurück zum Zitat Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657–64.CrossRefPubMed Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015;33(6):657–64.CrossRefPubMed
6.
Zurück zum Zitat Anagnostopoulos A, Hamilos G, Zorzou MP, Grigoraki V, Anagnostou D, Dimopoulos MA. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk Lymphoma. 2004;45(1):113–6.CrossRefPubMed Anagnostopoulos A, Hamilos G, Zorzou MP, Grigoraki V, Anagnostou D, Dimopoulos MA. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. Leuk Lymphoma. 2004;45(1):113–6.CrossRefPubMed
7.
Zurück zum Zitat Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.CrossRefPubMed Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–54.CrossRefPubMed
8.
Zurück zum Zitat Dutoit JC, Claus E, Offner F, Noens L, Delanghe J, Verstraete KL. Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma. Eur J Radiol. 2016;85(2):373–82.CrossRefPubMed Dutoit JC, Claus E, Offner F, Noens L, Delanghe J, Verstraete KL. Combined evaluation of conventional MRI, dynamic contrast-enhanced MRI and diffusion weighted imaging for response evaluation of patients with multiple myeloma. Eur J Radiol. 2016;85(2):373–82.CrossRefPubMed
9.
Zurück zum Zitat Dutoit JC, Verstraete KL. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging. 2016;7(4):553–69.CrossRefPubMedPubMedCentral Dutoit JC, Verstraete KL. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. Insights Imaging. 2016;7(4):553–69.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–66.CrossRefPubMedPubMedCentral Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European myeloma network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254–66.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Mangiacavalli S, Pezzatti S, Rossini F, Doni E, Cocito F, Bolis S, et al. Implemented myeloma management with whole-body low-dose CT scan: a real life experience. Leuk Lymphoma. 2016;57(7):1539–45.CrossRefPubMed Mangiacavalli S, Pezzatti S, Rossini F, Doni E, Cocito F, Bolis S, et al. Implemented myeloma management with whole-body low-dose CT scan: a real life experience. Leuk Lymphoma. 2016;57(7):1539–45.CrossRefPubMed
12.
Zurück zum Zitat Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, et al. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging. 2015;5(5):479–92.PubMedPubMedCentral Sachpekidis C, Mosebach J, Freitag MT, Wilhelm T, Mai EK, Goldschmidt H, et al. Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging. 2015;5(5):479–92.PubMedPubMedCentral
13.
Zurück zum Zitat Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD, et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer. 2007;109(8):1617–26.CrossRefPubMed Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD, et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer. 2007;109(8):1617–26.CrossRefPubMed
14.
Zurück zum Zitat Koutoulidis V, Fontara S, Terpos E, Zagouri F, Matsaridis D, Christoulas D, et al. Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma. Radiology. 2017;282(2):484–93.CrossRefPubMed Koutoulidis V, Fontara S, Terpos E, Zagouri F, Matsaridis D, Christoulas D, et al. Quantitative diffusion-weighted imaging of the bone marrow: an adjunct tool for the diagnosis of a diffuse MR imaging pattern in patients with multiple myeloma. Radiology. 2017;282(2):484–93.CrossRefPubMed
15.
Zurück zum Zitat Rahmouni A, Divine M, Mathieu D, Golli M, Haioun C, Dao T, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol. 1993;160(5):1053–7.CrossRefPubMed Rahmouni A, Divine M, Mathieu D, Golli M, Haioun C, Dao T, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol. 1993;160(5):1053–7.CrossRefPubMed
16.
Zurück zum Zitat Horger M, Thaiss WM, Ditt H, Weisel K, Fritz J, Nikolaou K et al. Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. Eur Radiol. 2017;27(7):2969–77. https://doi.org/10.1007/s00330-016-4642-6. Horger M, Thaiss WM, Ditt H, Weisel K, Fritz J, Nikolaou K et al. Improved MDCT monitoring of pelvic myeloma bone disease through the use of a novel longitudinal bone subtraction post-processing algorithm. Eur Radiol. 2017;27(7):2969–77. https://​doi.​org/​10.​1007/​s00330-016-4642-6.
17.
Zurück zum Zitat Horger M, Pereira P, Claussen CD, Kanz L, Vonthein R, Denecke B, et al. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol. 2008;81(965):386–96.CrossRefPubMed Horger M, Pereira P, Claussen CD, Kanz L, Vonthein R, Denecke B, et al. Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. Br J Radiol. 2008;81(965):386–96.CrossRefPubMed
18.
Zurück zum Zitat Viola P, Wells W. Alignment by maximization of mutual information. Int J Comput Vis. 1997;24(2):137–54.CrossRef Viola P, Wells W. Alignment by maximization of mutual information. Int J Comput Vis. 1997;24(2):137–54.CrossRef
19.
Zurück zum Zitat Viola P, Jones M. Robust real-time face detection. Int J Comput Vis. 2004;57(2):137–54.CrossRef Viola P, Jones M. Robust real-time face detection. Int J Comput Vis. 2004;57(2):137–54.CrossRef
20.
Zurück zum Zitat Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008;190(4):1097–104.CrossRefPubMed Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol. 2008;190(4):1097–104.CrossRefPubMed
21.
Zurück zum Zitat Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379–98.CrossRefPubMed Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379–98.CrossRefPubMed
22.
Zurück zum Zitat International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.CrossRef International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.CrossRef
23.
Zurück zum Zitat Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRefPubMed
24.
Zurück zum Zitat Schabel C, Horger M, Kum S, Weisel K, Fritz J, Ioanoviciu SD, et al. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography. Eur J Radiol. 2016;85(12):2195–9.CrossRefPubMed Schabel C, Horger M, Kum S, Weisel K, Fritz J, Ioanoviciu SD, et al. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography. Eur J Radiol. 2016;85(12):2195–9.CrossRefPubMed
25.
Zurück zum Zitat Bannas P, Hentschel HB, Bley TA, Treszl A, Eulenburg C, Derlin T, et al. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol 2012;22(9):2007–12. Bannas P, Hentschel HB, Bley TA, Treszl A, Eulenburg C, Derlin T, et al. Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation. Eur Radiol 2012;22(9):2007–12.
26.
Zurück zum Zitat Khoo MM, Tyler PA, Saifuddin A, Padhani AR. Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review. Skelet Radiol. 2011;40(6):665–81.CrossRef Khoo MM, Tyler PA, Saifuddin A, Padhani AR. Diffusion-weighted imaging (DWI) in musculoskeletal MRI: a critical review. Skelet Radiol. 2011;40(6):665–81.CrossRef
27.
Zurück zum Zitat Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol. 2011;196(6):W790–5.CrossRefPubMed Horger M, Weisel K, Horger W, Mroue A, Fenchel M, Lichy M. Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results. AJR Am J Roentgenol. 2011;196(6):W790–5.CrossRefPubMed
Metadaten
Titel
Comparison of qualitative and quantitative CT and MRI parameters for monitoring of longitudinal spine involvement in patients with multiple myeloma
verfasst von
M. Horger
J. Fritz
W. M. Thaiss
H. Ditt
K. Weisel
M. Haap
Christopher Kloth
Publikationsdatum
01.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 3/2018
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-017-2827-y

Weitere Artikel der Ausgabe 3/2018

Skeletal Radiology 3/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.